ArcelorMittal Down Over 7%, On Track for Largest Percent Decrease Since March 2023 — Data Talk
ArcelorMittal SA ADR (MT) is currently at $25.04, down $1.91 or 7.09%
--Would be lowest close since Nov. 29, 2023, when it closed at $25.04
--On pace for largest percent decrease since March 15, 2023, when it fell 8.85%
--Currently down four of the past five days
--Down 9.21% month-to-date
--Down 11.8% year-to-date
--Down 89.36% from its all-time closing high of $235.40 on June 5, 2008
--Down 16.62% from 52 weeks ago (April 18, 2023), when it closed at $30.03
--Down 16.62% from its 52-week closing high of $30.03 on April 18, 2023
--Up 16.57% from its 52-week closing low of $21.48 on Oct. 30, 2023
--Traded as low as $25.00; lowest intraday level since Nov. 30, 2023, when it hit $24.93
--Down 7.25% at today's intraday low; largest intraday percent decrease since March 15, 2023, when it fell as much as 10.38%
All data as of 1:34:57 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
April 16, 2024 13:54 ET (17:54 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track